AstraZeneca’s diabetes drug Forxiga (dapagliflozin) has been approved in the EU in patients with type 1 disease. Forxiga has been approved as an adjunct to insulin in patients with a BMI greater ...

The UK drugs regulator has meanwhile also approved the same indication for the drug. It is a sizeable new market for Forxiga – known as Farxiga in the US – as there are an estimated 47 million ...